Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3031323334353637383940...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Checkpoint inhibition, Metastases:  Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment. (Pubmed Central) -  Jun 5, 2023   
    LDM chemotherapy mostly modulates the tumor stroma rather than directly killing tumor cells. Here, we review the mechanism of LDM chemotherapy in terms of immune modulation and its potential as a combination partner with ICIs for the treatment of patients with mCRC tumors, most of which are immunologically cold.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, Adverse events:  Metabolic adverse events of multitarget kinase inhibitors: a systematic review. (Pubmed Central) -  Jun 5, 2023   
    Despite some inherent limitations, our analysis may cast light upon some of the MKIs metabolic disorders that can impact on patients' health, especially when long-term survival is expected. Future clinical trials should consider routine assessment of glucose and lipid levels, because underdetection and underreporting of alterations can lead to the overlooking of important adverse events.
  • ||||||||||  limantrafin (CB-103) / Cellestia Biotech, Lenvima (lenvatinib) / Eisai, Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    Enrollment open:  CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC (clinicaltrials.gov) -  Jun 5, 2023   
    P1/2,  N=34, Recruiting, 
    Future clinical trials should consider routine assessment of glucose and lipid levels, because underdetection and underreporting of alterations can lead to the overlooking of important adverse events. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) -  Jun 2, 2023   
    P2,  N=33, Active, not recruiting, 
    Initiation date: Jan 2022 --> May 2020 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Checkpoint inhibition:  Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report. (Pubmed Central) -  Jun 1, 2023   
    Herein, we reported an intrahepatic cholangiocarcinoma male patient with a history of ankylosing spondylitis developing pulmonary arterial hypertension (PAH) under ICI combined therapy with pembrolizumab and lenvatinib...The patient partially responded to the treatment of glucocorticoid and mycophenolate mofetil...We treated him with adalimumab -an antitumor necrosis factor-alpha (ani-TNF-?) antibody- combined with glucocorticoid and immunosuppressants under lenvatinib monotherapy...Accordingly, we diagnosed him to have irAE-related PAH. Our findings supported the use of glucocorticoid disease-modifying antirheumatic drugs (DMARDs) as a treatment option in refractory PAH.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial withdrawal, Combination therapy:  Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies (clinicaltrials.gov) -  Jun 1, 2023   
    P1,  N=0, Withdrawn, 
    Our findings supported the use of glucocorticoid disease-modifying antirheumatic drugs (DMARDs) as a treatment option in refractory PAH. N=70 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Enrollment open, Trial initiation date, Trial primary completion date:  HLPDTLT: Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation (clinicaltrials.gov) -  May 30, 2023   
    P2,  N=59, Recruiting, 
    These results suggest that ZLF-095 could become a potential angiogenesis inhibitor for cancer therapy. Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jul 2025 --> Aug 2027
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Development and in functional study of a bi-specific sustained release drug-loaded nano-liposomes for hepatocellular carcinoma. (Pubmed Central) -  May 27, 2023   
    Triple therapy of lenvatinib, PD-1 inhibitor, and TACE may achieve more favorable survival benefits than dual therapy of lenvatinib and PD-1 inhibitor in unresectable HCC patients with manageable safety profiles. In this study, an HCC-specific dual-targeted sustained-release drug delivery liposome with dual-targeted recognition and sensitive MRI tracer was successfully prepared, which provides an important scientific basis for maximizing the multiple effects of nano-carriers in tumor diagnosis and treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib in Neoadjuvant Setting (EXHIBIT HALL STATION B) -  May 26, 2023 - Abstract #WCTC2023WCTC_400;    
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker:  Combined use of pembrolizumab and lenvatinib: A review. (Pubmed Central) -  May 26, 2023   
    Use of non-chemotherapy containing regimens spare patients from extended durations of myelosuppression and reduce the risk of infection. Additionally, pembrolizumab with lenvatinib demonstrates efficacy as first line treatment in clear cell renal carcinoma, second line in endometrial carcinoma, and several potential uses on the horizon.
  • ||||||||||  MODULE 2: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HCC (Hilton Chicago; Grand Ballroom (Level 2)) -  May 26, 2023 - Abstract #ASCO2023ASCO_7070;    
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Merck, Seagen Inc, and Servier Pharmaceuticals LLC. Factors in the selection and sequencing of treatment for patients with advanced HCC whose disease has progressed on first-line and consecutive lines of therapy Role of multitargeted TKIs approved in the first-line setting, such as sorafenib and lenvatinib, for relapsed disease Long-term outcomes with approved anti-angiogenic agents for progressive HCC, including regorafenib, cabozantinib and ramucirumab Results from the Phase III KEYNOTE-394 trial and other pivotal studies examining the role of single-agent immune checkpoint inhibitors for R/R HCC Key findings with anti-PD-1/PD-L1 and anti-CTLA-4 combination regimens for progressive HCC Ongoing studies evaluating immune checkpoint inhibitor-based strategies for patients with HCC who have experienced disease progression on first-line atezolizumab/bevacizumab Other promising agents and strategies currently under investigation for HCC
  • ||||||||||  MODULE 1: First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC) and Biliary Tract Cancers (BTCs) (Hilton Chicago; Grand Ballroom (Level 2)) -  May 26, 2023 - Abstract #ASCO2023ASCO_7069;    
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Merck, Seagen Inc, and Servier Pharmaceuticals LLC. Recently presented results from the Phase III IMbrave050 study investigating atezolizumab/bevacizumab for patients with HCC at high risk of recurrence after surgical resection or ablation Clinical and biologic factors affecting the selection of up-front therapy for patients with advanced HCC Long-term findings from the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib as first-line therapy for unresectable HCC; optimal integration into routine practice Efficacy and safety outcomes reported with durvalumab/tremelimumab for previously untreated advanced HCC in the Phase III HIMALAYA study; recent FDA approval and current clinical role of this combination Mechanism of action of tislelizumab; similarities and differences with commercially available anti-PD-1/PD-L1 antibodies Available results from the Phase III RATIONALE 301 trial comparing tislelizumab to sorafenib as first-line treatment for advanced unresectable HCC; potential clinical role Current clinical utility of tyrosine kinase inhibitor (TKI) monotherapy as first-line treatment for unresectable HCC; available data demonstrating a potential advantage with lenvatinib compared to atezolizumab/bevacizumab for nonviral disease Major efficacy and safety findings with the addition of durvalumab to first-line chemotherapy for advanced BTCs in the Phase III TOPAZ-1 trial; FDA approval of up-front durvalumab and implications for clinical practice Recently presented results from the Phase III KEYNOTE-966 trial of pembrolizumab combined with cisplatin/gemcitabine compared to chemotherapy alone as first-line treatment for advanced BTCs; potential clinical role
  • ||||||||||  zabinostat (CXD101) / IngenOx Therap, Nuance Biotech
    New P2 trial, Checkpoint inhibition:  CXD101 in Immunotherapy-related Liver Cancer (clinicaltrials.gov) -  May 24, 2023   
    P2,  N=44, Not yet recruiting,